SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: Qualified Opinion who wrote (3406)10/19/2002 9:18:33 AM
From: Icebrg  Respond to of 10345
 
>>Per Biogen CC, if interim clinical trial results warrant it, Biogen hopes to make a submission of a NDA for Antegren in early 2004.>>

If? I suppose anyone can say that.

As Biogen doesn't know what the results are like, I wouldn't put too much weight to such a statement. The studies are double-blinded.

Ice



To: Qualified Opinion who wrote (3406)10/21/2002 4:41:32 PM
From: Qualified Opinion  Read Replies (2) | Respond to of 10345
 
October, 2002 short interest = 58 million shares

Link:http://www.nyse.com/marketinfo/nysestatistics.html#moshortint


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News